COVID-19 Update: UH has Afshin Dowlati, MD
Schedule an Appointment
Biography
- Lucile and Robert H Gries Endowed Director, Center for Cancer Drug Development
- Professor
- Disease Team Leader - Lung Cancer and Thoracic Scientific Team
- Director, Thoracic Oncology Program
Expertise
- Experimental Therapeutics
- Hematology/Oncology
- Lung Cancer
- Phase I Clinical Trials
- Thoracic Cancer
Languages Spoken
English, French, Farsi
Office Locations
Patient Satisfaction Reviews
4.8 out of 5
80 Ratings
Patient Comments (15)
Reviewed On 4/6/2020
Always a good experience with Dr. Dowlati and staff. [...]
Reviewed On 4/6/2020
always treated well.
Reviewed On 4/6/2020
Appreciated the sincere interest he showed to me during my visit. Was thorough and not rushed, and spent extra time answering our questions. Obviously he was seeking all the information I could provide to ensure my treatment plan was appropriate for me.
Reviewed On 4/6/2020
Dr Dowlati is very conscientious, personable, and thorough. Always takes the time to explain everything and reviews my complex medical history. He is truly an asset to your institution.
Reviewed On 4/6/2020
Excellent
Reviewed On 4/6/2020
good communication between doctor&myself.
Reviewed On 4/6/2020
Spent a lot of time with my dad. Very caring and explained things well
Reviewed On 4/6/2020
very helpful&freindly.
Reviewed On 4/6/2020
good
Reviewed On 4/6/2020
I find my doctor, his staff and receptionist to be curtious, compassionate, pleasant and refreshing to visit. I couldn't be in better hands for my care. Thank you all so much. respectfully, [...]
Reviewed On 4/6/2020
best dr and staff I've ever had!. [...]
Reviewed On 4/6/2020
can't say enough good about the care I received. Dr. Dowloti and his staff are second to none.
Reviewed On 4/6/2020
Dr, Dowlati and staff are always wonderful. [...] overall I feel like I'm getting great care from Dr Dowlati and his staff and feel like they truly care about me. Thank you for everything!
Reviewed On 4/6/2020
Excellent, professional and very comforting.
Reviewed On 4/6/2020
very smooth and never rushed.
Board Certifications
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Residency | Internal Medicine
Internal Medicine - University Hospitals Of Cleveland (1998 - 2000)
Fellowship | Hematology/Oncology
Hematology/Oncology - University Hospitals Of Cleveland (1996 - 1998)
Internship | Internal Medicine
Internal Medicine - Universite De Liege Faculte De Medecine (1992 - 1996)
Medical Education
Universite De Liege Faculte De Medecine (1992)
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Afshin Dowlati did not disclose any Outside Relationships with Industry.